Ajanta Pharma Q1 FY27: Revenue up 25%, Rs 32 interim dividend declared
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma Q1 FY27: Revenue up 25% at Rs 1,626 cr, PAT up 31% at Rs 334 cr. Adjusted EBITDA Rs 454 cr with 28% margin. India branded generics grew 24%, US generics 57%, Africa 30%, Asia declined 16% on war impact. Board declared 1st interim dividend of Rs 32 per share totaling Rs 400 cr. Record date Aug 5, payment from Aug 18. ROCE 37%, RONW 28%. Auditors gave unmodified opinion but flagged pending income tax search.
Strong Q1 with 25% revenue and 31% PAT growth. Rs 32 dividend signals robust cash flows. Income tax search remains an overhang.